Private equity has spent years consolidating dermatology, orthopedics, and dental practices. Now it has set its sights on neurology – a specialty that, until recently, flew largely under the radar of financial acquirers.
Why Neurology, Why Now
The appeal is structural. Neurology practices generate recurring, high-frequency patient visits tied to chronic conditions – multiple sclerosis, epilepsy, Parkinson’s disease, migraines – that require long-term management rather than one-time interventions. That kind of predictable, repeat-visit revenue is exactly what private equity roll-up models are built to absorb. Unlike a surgical specialty where volume depends on procedure schedules, a neurology practice treating a patient with MS may see that person six to twelve times a year for decades.
Staffing pressure is pushing neurologists toward the exits faster than many anticipated. The specialty has faced a widening gap between patient demand and available physicians for years, and running an independent practice while managing billing, compliance, electronic records, and staffing has become genuinely exhausting for many solo and small-group operators. A buyout offer, especially one that promises administrative relief and a continued clinical role, becomes harder to refuse when the alternative is managing a practice that feels less like medicine and more like a small business struggling against rising overhead.
The math also works unusually well for acquirers in this space. Neurology reimbursement rates have gradually improved as payers recognized the cost savings from managing chronic neurological conditions proactively rather than reactively. At the same time, the diagnostic side – EEGs, nerve conduction studies, sleep studies often bundled into neurology care – generates ancillary revenue streams that a well-capitalized platform can scale quickly across multiple locations. A private equity firm acquiring a ten-physician neurology group is not just buying a clinical practice; it is buying a diagnostic facility, a prescription management operation, and a patient database with years of longitudinal records.
Geographic concentration matters too. Many of the most attractive acquisition targets are regional practices that built dominant market positions in mid-sized cities where they face limited competition – places where one neurology group effectively controls access to specialist care for a metropolitan area of several hundred thousand people. Acquiring that group does not just add revenue; it adds pricing leverage with hospital systems and payers that depend on those neurologists for patient referrals and inpatient consults.
How the Deals Actually Work
The acquisition structure in neurology follows the same playbook seen across regional specialty practice roll-ups in other fields. A private equity firm creates or acquires a platform company – typically an existing neurology group with professional management already in place – and uses that platform to buy smaller practices at lower multiples. The founding physicians usually receive a cash payment for the majority of their equity, retain a smaller stake in the new platform, and sign employment agreements that keep them practicing at their existing locations. The pitch is that physicians get liquidity now, relief from administrative burdens immediately, and a second payout if and when the platform sells to a larger acquirer or goes public.
The employment agreements are where the tension often surfaces. Neurologists who sell frequently describe a honeymoon period of twelve to eighteen months where the promised administrative support arrives and clinical autonomy feels intact. After that, the operational pressure begins. Productivity benchmarks replace the flexibility of independent practice. Patient panel sizes increase. Documentation requirements tighten to optimize billing codes. The specialist who sold partly to escape the grind of running a business finds that the grind has simply changed shape.
Compensation structures shift in ways that are not always obvious at signing. Many deals convert physicians from profit-sharing partners to productivity-based employees, meaning total compensation becomes more directly tied to relative value units – the billing metric that governs how Medicare and commercial insurers pay for physician work. In a specialty like neurology, where complex cognitive evaluations take substantial time but generate fewer RVUs than procedural work, this can quietly erode earnings for physicians whose practices leaned toward thoughtful diagnostic medicine rather than high-volume throughput.
Payer negotiations change after acquisition as well. A private equity-backed platform with neurology practices across multiple markets can negotiate managed care contracts at scale in ways a regional group never could. This cuts both ways. Larger platforms often extract better reimbursement rates, which benefits the bottom line. But payers increasingly push back with narrow network contracts and prior authorization requirements that add administrative friction – friction that falls on clinical staff even when the deal promised to reduce it.
Patient experience sits at the center of a real unresolved question about this model. Neurological conditions are intensely personal, and patients with chronic diagnoses often build relationships with their neurologist over many years. When a practice sells, the physician may stay, but the support staff turns over, the scheduling system changes, the phone system changes, and the billing office moves to a centralized operation in another state. The clinical relationship may persist while everything around it becomes unfamiliar – a combination that generates complaints even when the medical care itself remains unchanged.
What Comes Next
The consolidation wave in neurology is probably in its early stages rather than its middle ones. Dermatology went through its most aggressive roll-up period from roughly 2015 to 2022, and neurology appears to be roughly five to seven years behind that curve. That means many independent practices that feel insulated right now – because they have not yet been approached, or because early offers were below expectations – will face a different decision environment as platforms grow larger and the remaining independent groups become more valuable simply by virtue of their scarcity.
What independent neurologists are watching closely is whether hospital systems accelerate their own physician acquisition activity in response. If private equity-backed platforms gain enough market share in neurology, health systems that depend on those specialists for neurology coverage and inpatient consults face a strategic problem: they either acquire practices themselves to secure access, or they negotiate with a platform that now has real leverage over them. That competition between private equity and hospital systems for the remaining independent neurology groups could drive acquisition prices higher – which benefits the physicians selling now least, and the ones who wait longest the most.
